Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with colorectal cancer: a meta-analysis
Corresponding Author(s) : Lei Wang
Cellular and Molecular Biology,
Vol. 64 No. 6: Advances in mechanism and treatment strategy of cancer
Abstract
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- Stewart B, Wild CP. World cancer report 2014. Health 2017.
- McAllister F, Housseau F, Sears CL. Microbiota and immune responses in colon cancer: more to learn. Cancer journal (Sudbury, Mass) 2014; 20(3): 232.
- Kimura A, Naka T, Kishimoto T. IL-6-dependent and-independent pathways in the development of interleukin 17-producing T helper cells. Proceedings of the National Academy of Sciences 2007; 104(29): 12099-12104.
- Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21(4): 467-476.
- Liu SJ, Tsai JP, Shen CR et al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor"β and interleukin"6. Journal of leukocyte biology 2007; 82(2): 354-360.
- Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. The Journal of Immunology 2010; 184(3): 1630-1641.
- Guo Q, Shen S, Li X, Tang K, Zhou W. Inflammatory factors promote the development of colorectal cancer. Zhong nan da xue xue bao Yi xue ban= Journal of Central South University Medical sciences 2011; 36(7): 646-649.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Revista Española De Nutrición Humana Y Dietética 2009; 18(3): e123.
- Mcpheeters ML. Newcastle-Ottawa Quality Assessment Scale. 2012.
- DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary clinical trials 2007; 28(2): 105-114.
- Higgins J, Thompson SG. Quantifying heterogeneity in a meta"analysis. Statistics in medicine 2002; 21(11): 1539-1558.
- Zhang J. [Th17 cells and related cytokines expression in elderly colon cancer patients]. Chongqing Medical Journal 2016; 36(9).
- ZHANG Li-li ZY-z, ZHANG Cai-feng,XIA Yong-hua, CHANG Ting-min, HAN Yu. [Expression of Th17 and CD4+ CD25+ regulatory T cells in the peripheral blood of patients with colon cancer]. China Journal of Modern Medicine 2014; 24(11): 59-62.
- Guofang L. Expression of CD4+T cell subsets in colorectal carcinoma and their clinical significance, YANGZHOU UNIVERSITY; 2014.
- Lei Y. [Distribution and clinical significance of Th17 cells in colorectal cancer patients] SU ZHOU UNIVERSITY; 2016.
- Xinyi L. [Alteration of the Percentage of T Helper 17 Lymphocytes and Interleukin-6 and -17 Expression in Elderly Colorectal Cancer Patients], DaLian Medical University; 2014.
- Huang jiahao Cy, Gao feng. [Detection of Th1 and Th2 cells in peripheral blood of the colorectal cancer patients]. Journal of Colorectal & Anal Surgery 2012; 18(2): 71-79.
- al. ZXWXPQe. [The expression and clinical significance of serum IL-17 in colorectal cancer]. MMJC 2014; (4): 36-39.
- Mengjie WANG SS, Keqing QIAN, Haiyan MIN, Ling CEN, Chunjian QI. [Preliminary studies on the serum IL-17 and TGF-β levels and their correlations with tumor incidence and progression in colorectal cancer patients]. Chin J Clin Oncol 2013; (13): 767-769.
- Hui M, Fei P, Guo H et al. Feedback mechanisms between M2 macrophages and Th17 cells in colorectal cancer patients. Tumor Biology 2016; 37(9): 12223-12230.
- Radosavljevic GB, Jovanovic. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 2010; 57(2): 135.
- LI Shubin SD. The distribution of peripheral Th17 and Th22 cells and the roles of IL-17A and IL-22 in colon cancer patients. Chinese Journal of Gastroenterology and Hepatology 2017; 26(8): 882-885.
- WANG Jian-Sheng TY-Q, ZHANG Li-Zhi,L Yuan-Peng,SONG Jin-Xiao. Changes of circulating Tc17 cells in progression of colorectal cancer. Chinese Journal of Immunology 2014; (6): 817-820.
- WANG Jiansheng ZL, TIE Yanqing, LYU Yuanpeng, SONG Jinxiao. [The Changes of Circulating Th17 and Tc17 Cells in Patients with Colorectal Polyp Adenoma and Cancer]. Tianjin Med J 2014; 42(4): 312-314.
- HUANG Wei-gang CR-c, XIANG Jia-liang,ZHANG Guo-an. . Expressions of serum IL-17 and IL-6 of patients with colorectal carcinoma and their clinical significance. TUMOR 2012; 32(6): 458-461.
- Jiansheng WANG YL, Juntao MENG, Jinxiao SONG, Lizhi ZHANG, Yanqing TIE. Expression and clinical significance of IL-23 and IL-17 in patients with colorectal cancer. Chinese Journal of Clinical Oncology 2014; (9): 580-584.
- Adamo V, Franchina T, Minciullo PL et al. Role of interleukin"23 circulating levels increase in resected colorectal cancer before and after chemotherapy: Preliminary data and future perspectives. Journal of Cellular Physiology 2011; 226(11): 3032-3034.
- Alizadeh D, Katsanis E, Larmonier N. The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer. Clinical and Developmental Immunology 2013; 2013.
- Ghosh S, Ashcraft K. An IL-6 link between obesity and cancer. Frontiers in bioscience (Elite edition) 2013; 5: 461-478.
- Li L, Boussiotis VA. The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer. Clinical immunology 2013; 148(2): 246-253.
- Fu B, Tian Z, Wei H. TH17 cells in human recurrent pregnancy loss and pre-eclampsia. Cellular & molecular immunology 2014; 11(6): 564.
- Tosolini M, Kirilovsky A, Mlecnik B et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer research 2011; 71(4): 1263-1271.
- Le Gouvello S, Bastuji-Garin S, Aloulou N et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008; 57(6): 772-779.
- Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells. Nature immunology 2007; 8(9): 942.
- Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nature immunology 2009; 10(8): 857.
- Buonocore S, Ahern PP, Uhlig HH et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464(7293): 1371.
- Das J, Ren G, Zhang L et al. Transforming growth factor β is dispensable for the molecular orchestration of Th17 cell differentiation. Journal of Experimental Medicine 2009; 206(11): 2407-2416.
- Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. Journal of Experimental Medicine 2005; 201(2): 233-240.
- Manel N, Unutmaz D, Littman DR. The differentiation of human T H-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nature immunology 2008; 9(6): 641.
- Santarlasci V, Maggi L, Capone M et al. TGF"β indirectly favors the development of human Th17 cells by inhibiting Th1 cells. European journal of immunology 2009; 39(1): 207-215.
- Mangan PR, Harrington LE, O'quinn DB et al. Transforming growth factor-β induces development of the T H 17 lineage. Nature 2006; 441(7090): 231.
- Teraishi F, Ozaki K, Shibuya Y et al. Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient. Gan to kagaku ryoho Cancer & chemotherapy 2012; 39(3): 473-475.
- Kouroussis C, Souglakos J, Kakolyris S et al. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 2001; 61(1): 36-41.
References
Stewart B, Wild CP. World cancer report 2014. Health 2017.
McAllister F, Housseau F, Sears CL. Microbiota and immune responses in colon cancer: more to learn. Cancer journal (Sudbury, Mass) 2014; 20(3): 232.
Kimura A, Naka T, Kishimoto T. IL-6-dependent and-independent pathways in the development of interleukin 17-producing T helper cells. Proceedings of the National Academy of Sciences 2007; 104(29): 12099-12104.
Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21(4): 467-476.
Liu SJ, Tsai JP, Shen CR et al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor"β and interleukin"6. Journal of leukocyte biology 2007; 82(2): 354-360.
Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. The Journal of Immunology 2010; 184(3): 1630-1641.
Guo Q, Shen S, Li X, Tang K, Zhou W. Inflammatory factors promote the development of colorectal cancer. Zhong nan da xue xue bao Yi xue ban= Journal of Central South University Medical sciences 2011; 36(7): 646-649.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Revista Española De Nutrición Humana Y Dietética 2009; 18(3): e123.
Mcpheeters ML. Newcastle-Ottawa Quality Assessment Scale. 2012.
DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemporary clinical trials 2007; 28(2): 105-114.
Higgins J, Thompson SG. Quantifying heterogeneity in a meta"analysis. Statistics in medicine 2002; 21(11): 1539-1558.
Zhang J. [Th17 cells and related cytokines expression in elderly colon cancer patients]. Chongqing Medical Journal 2016; 36(9).
ZHANG Li-li ZY-z, ZHANG Cai-feng,XIA Yong-hua, CHANG Ting-min, HAN Yu. [Expression of Th17 and CD4+ CD25+ regulatory T cells in the peripheral blood of patients with colon cancer]. China Journal of Modern Medicine 2014; 24(11): 59-62.
Guofang L. Expression of CD4+T cell subsets in colorectal carcinoma and their clinical significance, YANGZHOU UNIVERSITY; 2014.
Lei Y. [Distribution and clinical significance of Th17 cells in colorectal cancer patients] SU ZHOU UNIVERSITY; 2016.
Xinyi L. [Alteration of the Percentage of T Helper 17 Lymphocytes and Interleukin-6 and -17 Expression in Elderly Colorectal Cancer Patients], DaLian Medical University; 2014.
Huang jiahao Cy, Gao feng. [Detection of Th1 and Th2 cells in peripheral blood of the colorectal cancer patients]. Journal of Colorectal & Anal Surgery 2012; 18(2): 71-79.
al. ZXWXPQe. [The expression and clinical significance of serum IL-17 in colorectal cancer]. MMJC 2014; (4): 36-39.
Mengjie WANG SS, Keqing QIAN, Haiyan MIN, Ling CEN, Chunjian QI. [Preliminary studies on the serum IL-17 and TGF-β levels and their correlations with tumor incidence and progression in colorectal cancer patients]. Chin J Clin Oncol 2013; (13): 767-769.
Hui M, Fei P, Guo H et al. Feedback mechanisms between M2 macrophages and Th17 cells in colorectal cancer patients. Tumor Biology 2016; 37(9): 12223-12230.
Radosavljevic GB, Jovanovic. Interleukin-17 may be a valuable serum tumor marker in patients with colorectal carcinoma. Neoplasma 2010; 57(2): 135.
LI Shubin SD. The distribution of peripheral Th17 and Th22 cells and the roles of IL-17A and IL-22 in colon cancer patients. Chinese Journal of Gastroenterology and Hepatology 2017; 26(8): 882-885.
WANG Jian-Sheng TY-Q, ZHANG Li-Zhi,L Yuan-Peng,SONG Jin-Xiao. Changes of circulating Tc17 cells in progression of colorectal cancer. Chinese Journal of Immunology 2014; (6): 817-820.
WANG Jiansheng ZL, TIE Yanqing, LYU Yuanpeng, SONG Jinxiao. [The Changes of Circulating Th17 and Tc17 Cells in Patients with Colorectal Polyp Adenoma and Cancer]. Tianjin Med J 2014; 42(4): 312-314.
HUANG Wei-gang CR-c, XIANG Jia-liang,ZHANG Guo-an. . Expressions of serum IL-17 and IL-6 of patients with colorectal carcinoma and their clinical significance. TUMOR 2012; 32(6): 458-461.
Jiansheng WANG YL, Juntao MENG, Jinxiao SONG, Lizhi ZHANG, Yanqing TIE. Expression and clinical significance of IL-23 and IL-17 in patients with colorectal cancer. Chinese Journal of Clinical Oncology 2014; (9): 580-584.
Adamo V, Franchina T, Minciullo PL et al. Role of interleukin"23 circulating levels increase in resected colorectal cancer before and after chemotherapy: Preliminary data and future perspectives. Journal of Cellular Physiology 2011; 226(11): 3032-3034.
Alizadeh D, Katsanis E, Larmonier N. The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer. Clinical and Developmental Immunology 2013; 2013.
Ghosh S, Ashcraft K. An IL-6 link between obesity and cancer. Frontiers in bioscience (Elite edition) 2013; 5: 461-478.
Li L, Boussiotis VA. The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer. Clinical immunology 2013; 148(2): 246-253.
Fu B, Tian Z, Wei H. TH17 cells in human recurrent pregnancy loss and pre-eclampsia. Cellular & molecular immunology 2014; 11(6): 564.
Tosolini M, Kirilovsky A, Mlecnik B et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer research 2011; 71(4): 1263-1271.
Le Gouvello S, Bastuji-Garin S, Aloulou N et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 2008; 57(6): 772-779.
Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cells. Nature immunology 2007; 8(9): 942.
Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nature immunology 2009; 10(8): 857.
Buonocore S, Ahern PP, Uhlig HH et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464(7293): 1371.
Das J, Ren G, Zhang L et al. Transforming growth factor β is dispensable for the molecular orchestration of Th17 cell differentiation. Journal of Experimental Medicine 2009; 206(11): 2407-2416.
Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. Journal of Experimental Medicine 2005; 201(2): 233-240.
Manel N, Unutmaz D, Littman DR. The differentiation of human T H-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt. Nature immunology 2008; 9(6): 641.
Santarlasci V, Maggi L, Capone M et al. TGF"β indirectly favors the development of human Th17 cells by inhibiting Th1 cells. European journal of immunology 2009; 39(1): 207-215.
Mangan PR, Harrington LE, O'quinn DB et al. Transforming growth factor-β induces development of the T H 17 lineage. Nature 2006; 441(7090): 231.
Teraishi F, Ozaki K, Shibuya Y et al. Marked response to oral administration of UFT and leucovorin for liver metastases from colon cancer in an elderly patient. Gan to kagaku ryoho Cancer & chemotherapy 2012; 39(3): 473-475.
Kouroussis C, Souglakos J, Kakolyris S et al. Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 2001; 61(1): 36-41.